EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vaccine failure mode determines population-level impact of vaccination campaigns during epidemics

Da In Lee, Anjalika Nande iD, Thayer L Anderson, Michael Z Levy iD, Alison L Hill iD

Journal of The Royal Society Interface · 2025-02 · 22 (223)

DOI: 10.1098/rsif.2024.0689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of The Royal Society Interface, online erschienen am 19.02.2025. Verfasst von Da In Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, COVID-19 Vaccines, Vaccination. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccines are a crucial tool for controlling infectious diseases, yet rarely offer perfect protection. ‘Vaccine efficacy’ describes a population-level effect measured in clinical trials, but mathematical models used to evaluate the impact of vaccination campaigns require specifying how vaccines fail at the individual level, which is often impossible to measure. Does 90% efficacy imply perfect protection in 90% of people and no protection in 10% (‘all-or-nothing’) or that the per-exposure risk is reduced by 90% in all vaccinated individuals (‘leaky’) or somewhere in between? Here, we systematically investigate the role of vaccine failure mode in controlling ongoing epidemics. We find that the difference in population-level impact between all-or-nothing and leaky vaccines can be substantial when R 0 is higher, vaccines efficacy is intermediate, and vaccines slow but cannot curtail an outbreak. Comparing COVID-19 pandemic phases, we show times when model predictions would have been most sensitive to assumptions about vaccine failure mode. When determining the optimal risk group to prioritize for limited vaccines, we find that modelling a leaky vaccine as all-or-nothing (or vice versa) can change the recommended target group. Overall, we conclude that models of vaccination campaigns should include uncertainty about vaccine failure mode in their design and interpretation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2COVID-19 VaccinesVaccinationEpidemicsImmunization ProgramsVaccine EfficacyModels, BiologicalHumansPandemics

Stichwörter der Autor:innen

COVID-19epidemiologyinfectious diseasemathematical modellingvaccine efficacy

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD, USA.
  • Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
  • Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

ORCID-Profile: Anjalika Nande, Michael Z Levy, Alison L Hill

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • CDC HHS
  • Centers for Disease Control and Prevention
  • National Institutes of Health

Zitieren

APA

Lee, D. I., Nande, A., Anderson, T. L., Levy, M. Z., & Hill, A. L. (2025). Vaccine failure mode determines population-level impact of vaccination campaigns during epidemics. Journal of The Royal Society Interface, 22(223). https://doi.org/10.1098/rsif.2024.0689

Vancouver

Lee DI, Nande A, Anderson TL, Levy MZ, Hill AL. Vaccine failure mode determines population-level impact of vaccination campaigns during epidemics. Journal of The Royal Society Interface. 2025;22(223). doi:10.1098/rsif.2024.0689

BibTeX
@article{Lee2025,
  author = {Lee, Da In and Nande, Anjalika and Anderson, Thayer L and Levy, Michael Z and Hill, Alison L},
  title = {Vaccine failure mode determines population-level impact of vaccination campaigns during epidemics},
  journal = {Journal of The Royal Society Interface},
  year = {2025},
  volume = {22},
  number = {223},
  doi = {10.1098/rsif.2024.0689}
}
Kostenlos starten →